PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA
X. Zhen,S. Gu,X. Sun,X. Hu,Y. Gu,H. Dong
DOI: https://doi.org/10.1016/J.JVAL.2020.04.803
IF: 5.156
2020-01-01
Value in Health
Abstract:Carbapenem-resistant gram-negative organisms, which were classified as critical organisms in WHO priority ranking list of antibiotic resistant organisms are difficult to treat. In China, the proportion of A. baumannii, P. aeruginosa, K. pneumonia isolates that were carbapenem-resistant A. baumannii (CRAB), carbapenem-resistant P. aeruginosa (CRPA), carbapenem-resistant K. pneumonia (CRKP) were 59.0%, 22.4%, and 7.6%, respectively. The clinical and economic outcomes of CRAB, CRPA, and CRKP are largely uninvestigated. This study aimed to compare the differences in hospital cost, length of stay, and hospital mortality among inpatients with CRAB and carbapenem-susceptible A. baumannii (CSAB), CRPA and carbapenem-susceptible P. aeruginosa (CSPA), and CRKP and carbapenem-susceptible K. pneumonia (CSKP). A retrospective and multicenter study of inpatients with antibiotic positive clinical samples was conducted in four tertiary hospitals in China during 2013 and 2015. Propensity score matching was conducted to balance the potential confounding variables, and to explore the main indicators including hospital cost, length of stay, and hospital mortality. Monte Carlo simulations with 1,000 iterations were run to calculate 95% uncertainty intervals. A total of 1,665 inpatients with CRAB and 1,280 with CSAB, 1,244 with CRPA and 2,674 with CSPA, 831 with CRKP and 4,328 with CSKP were included. PSM generated 682, 1,155, 822 pairs between CRAB and CSAB group, CRPA and CSPA group, and CRKP and CSKP group, respectively. After PSM, increased total hospital cost of $7,277, $4,605, $14,252 were observed in inpatients caused by CRAB. CRPA, and CRKP colonization and infection. Excess length of stay of 15.8 days, 5.4 days, and 13.2 days were found among inpatients with CRAB, CRPA, and CRKP, which were also associated with attributable hospital mortality of 4.03%, 2.03%, and 2.94%. Our study highlights the heavy clinical and economic outcomes imposed by A. baumannii, P. aeruginosa, K. pneumonia and carbapenem resistance on the Chinese healthcare system.